Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial [published correction appears in Lancet
MRP1-dependent collateral sensitivity of multidrug-resistant cancer cells: identifying selective modulators inducing cellular glutathione depletion
Vicki Belo herself for 2,000
Smart use of dosing tools, adaptive strategies, and regular monitoring help us get the most from peptide therapy and avoid risks
How bright our future will be depends on how much we safeguard the natural world, and the health of the ecosystems within which we all live.
However, starting at low doses and coordinating closely with your bariatric surgeon minimizes any adverse effects